174 related articles for article (PubMed ID: 10820360)
21. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation.
Vassilakopoulou M; Mountzios G; Papamechael C; Protogerou AD; Aznaouridis K; Katsichti P; Venetsanou K; Dimopoulos MA; Ikonomidis I; Papadimitriou CA
Vascul Pharmacol; 2010; 53(3-4):115-21. PubMed ID: 20470900
[TBL] [Abstract][Full Text] [Related]
24. [A Case of a Suspected Photosensitive Reaction Induced by Weekly Paclitaxel as Neoadjuvant Chemotherapy for Breast Cancer].
Watanabe H; Hoshi I; Nakai Y; Yamasaki K; Abe H
Gan To Kagaku Ryoho; 2015 Aug; 42(8):981-4. PubMed ID: 26321713
[TBL] [Abstract][Full Text] [Related]
25. [Weekly paclitaxel therapy for metastatic breast cancer].
Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
[TBL] [Abstract][Full Text] [Related]
26. [Preclinical and clinical results in the simultaneous radiochemotherapy of head and neck tumors with Paclitaxel].
Hoffmann W; Heinrich V; Belka C; Budach W; Schmidberger H; Bochtler H; Rodemann HP; Bamberg M
Strahlenther Onkol; 1996 May; 172 Suppl 1():15-20. PubMed ID: 8633268
[No Abstract] [Full Text] [Related]
27. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
28. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
29. Dose-intensified weekly paclitaxel induces multiple nail disorders.
Lüftner D; Flath B; Akrivakis C; Schweigert M; Prinz B; Mergenthaler HG; Petrides PE; Wernecke KD; Possinger K
Ann Oncol; 1998 Oct; 9(10):1139-40. PubMed ID: 9834830
[No Abstract] [Full Text] [Related]
30. Onycholysis associated with paclitaxel.
Mackay-Wiggan J; Nair KG; Halasz CL
Cutis; 2003 Mar; 71(3):229-32. PubMed ID: 12661751
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
[TBL] [Abstract][Full Text] [Related]
32. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
34. Drug interactions with the taxanes: clinical implications.
Baker AF; Dorr RT
Cancer Treat Rev; 2001 Aug; 27(4):221-33. PubMed ID: 11545542
[TBL] [Abstract][Full Text] [Related]
35. Nail changes secondary to docetaxel (Taxotere).
Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
[TBL] [Abstract][Full Text] [Related]
36. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R; Biganzoli L; Bruning P; Klijn JG; Gamucci T; Houston S; Coleman R; Schachter J; Van Vreckem A; Sylvester R; Awada A; Wildiers J; Piccart M
J Clin Oncol; 2000 Feb; 18(4):724-33. PubMed ID: 10673513
[TBL] [Abstract][Full Text] [Related]
38. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
39. [Weekly paclitaxel administration in the adjuvant therapy of primary breast cancer].
Takahashi H; Takahashi M; Taguchi K; Sasaki F; Todo S
Gan To Kagaku Ryoho; 2003 May; 30(5):653-9. PubMed ID: 12795097
[TBL] [Abstract][Full Text] [Related]
40. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
